PMID- 12691778
OWN - NLM
STAT- MEDLINE
DCOM- 20030623
LR  - 20220309
IS  - 0278-5846 (Print)
IS  - 0278-5846 (Linking)
VI  - 27
IP  - 3
DP  - 2003 May
TI  - Substrate kinetics of erythrocyte membrane Na,K-ATPase and lipid peroxides in 
      schizophrenia.
PG  - 431-40
AB  - Previous studies have shown decreased erythrocyte membrane (EM) Na,K-ATPase 
      activity in chronic patients suffering from schizophrenia (SCH). There are no 
      data about changes at the onset of psychosis and enzyme kinetics. Increased lipid 
      peroxidation could be responsible for alterations in Na,K-ATPase activity. 
      Substrate kinetics pattern of EM Na,K-ATPase and levels of lipid peroxides in 
      plasma and erythrocytes were measured in (1) patients with first episode of 
      psychosis (n=20) before medication and after the first 3 weeks of treatment, (2) 
      chronic medicated schizophrenic patients (n=52) in the exacerbation phase, and 
      (3) age- and sex-matched control subjects (n=30). All patients were assigned to 
      groups with predominantly positive or predominantly negative symptoms on the 
      basis of their scores on Positive and Negative Syndrome Scale (PANSS). In 
      first-episode patients with predominantly negative symptoms before treatment, 
      uncompetitive inhibition of Na,K-ATPase was noticed. The first-episode patients 
      with predominantly positive symptoms had increased enzyme catalytic activity. 
      After 3 weeks of treatment, activities were normalized in both groups. Among 
      chronic patients, uncompetitive inhibition was found only in patients with 
      predominantly negative symptoms. Plasma lipid peroxides (thiobarbituric 
      acid-reactive substances [TBARS]) were elevated in both groups of patients with 
      first episode of psychosis. Despite the presence of peroxidative injury 
      indicative for the loss of membrane phospholipid essential fatty acids, the 
      activities of Na,K-ATPase differ between SCH (+) and SCH (-) patients.
FAU - Petronijevic, Natasa D
AU  - Petronijevic ND
AD  - Institute of Biochemistry, Faculty of Medicine, Belgrade, Yugoslavia.
FAU - Micic, Dejan V
AU  - Micic DV
FAU - Duricic, Bogdan
AU  - Duricic B
FAU - Marinkovic, Dragan
AU  - Marinkovic D
FAU - Paunovic, Vladimir R
AU  - Paunovic VR
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Prog Neuropsychopharmacol Biol Psychiatry
JT  - Progress in neuro-psychopharmacology & biological psychiatry
JID - 8211617
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Lipid Peroxides)
RN  - EC 7.2.2.13 (Sodium-Potassium-Exchanging ATPase)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Analysis of Variance
MH  - Antipsychotic Agents/pharmacology/therapeutic use
MH  - Erythrocyte Membrane/*enzymology
MH  - Humans
MH  - Lipid Peroxides/*blood
MH  - Male
MH  - Middle Aged
MH  - Schizophrenia/*blood/drug therapy/*enzymology
MH  - Sodium-Potassium-Exchanging ATPase/*blood
MH  - Substrate Specificity/drug effects/physiology
EDAT- 2003/04/15 05:00
MHDA- 2003/06/24 05:00
CRDT- 2003/04/15 05:00
PHST- 2003/04/15 05:00 [pubmed]
PHST- 2003/06/24 05:00 [medline]
PHST- 2003/04/15 05:00 [entrez]
AID - S0278584603000307 [pii]
AID - 10.1016/s0278-5846(03)00030-7 [doi]
PST - ppublish
SO  - Prog Neuropsychopharmacol Biol Psychiatry. 2003 May;27(3):431-40. doi: 
      10.1016/s0278-5846(03)00030-7.